Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16847608 | 0.91 | MAPT (0.49) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL19017845 | 0.91 | MAPT (0.49) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL16847607 | 0.86 | MAPT (0.49) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL12285414 | 0.83 | PSMB8 (0.47) | CA1CA2MAPTTDP1NPSR1 | |
| SCHEMBL14378788 | 0.83 | CA1 (0.59) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL28074876 | 0.81 | CA1 (0.57) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL16486871 | 0.81 | MEN1 (0.52) | MAPTTDP1NPSR1KMT2AGAA | |
| SCHEMBL29773945 | 0.81 | MEN1 (0.52) | MAPTTDP1NPSR1KMT2AGAA | |
| SCHEMBL16486872 | 0.81 | MEN1 (0.52) | MAPTTDP1NPSR1KMT2AGAA | |
| SCHEMBL13465348 | 0.79 | SIRT5 (0.56) | CA1CA2MAPTTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3782654-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3191135-B1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200255539-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. | 2020-02-11 | — | — | US | disclosed |
| US-20190177429-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| EP-3033111-B1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | GENENTECH INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10179820-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-10017577-B2 | Antibodies and immunoconjugates | GENENTECH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170174782-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9518118-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179820-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885MAPT 1689/4885 |
| US-20190177429-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885MAPT 1689/4885 |
| US-10017577-B2 | Antibodies and immunoconjugates | FCGR3B, CD47, FCGR1A | CA1 1600/4885CA2 3167/4885MAPT 1194/4885 |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885MAPT 1689/4885 |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885MAPT 1689/4885 |
| US-20200255539-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885MAPT 1689/4885 |
| US-20170174782-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885MAPT 1689/4885 |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | CA1 2162/4885CA2 983/4885MAPT 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.